A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

NCT03821233 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-expressing Cancers

Interventions

DRUG: ZW49

Sponsor

Zymeworks BC Inc.